Company intelligence / Profile preview

Cognoa

Palo Alto, California, United Statescognoa.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cognoa’s Canvas Dx is the first FDA-authorized digital diagnostic solution for autism in children ages 1.5 to 6 years. Clinical studies demonstrated high accuracy across genders, ethnicities, and backgrounds, exceeding all pre-specified endpoints. The tool enables rapid diagnosis within days instead of months or years, supporting earlier intervention. It has received De Novo classification from the FDA. Canvas Dx is now commercially available and reimbursed by insurers such as Highmark.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceDigital therapeutic
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

Canvas Dx

Commercial

Indications: Autism spectrum disorder

Partnerships

Health Transformation AllianceAutism Learning Partners

Beyond the preview

Go deeper on Cognoa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognoa.

Explore the full profile